Roche Holding AG (SWX:ROP)
333.80
+5.00 (1.52%)
Jul 2, 2026, 1:27 PM CET
Roche Holding AG Revenue
In the year 2025, Roche Holding AG had annual revenue of 63.36B CHF with 1.54% growth. Roche Holding AG had revenue of 31.51B in the half year ending December 31, 2025, with 5.64% growth.
Revenue
63.36B
Revenue Growth
+1.54%
P/S Ratio
4.14
Revenue / Employee
613.62K
Employees
103,249
Market Cap
262.18B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 63.36B | 961.00M | 1.54% |
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novartis AG | 45.38B |
| Sandoz Group AG | 8.85B |
| Alcon | 8.53B |
| Lonza Group AG | 6.53B |
| Galderma Group AG | 4.16B |
| Galenica AG | 4.15B |
| Sonova Holding AG | 3.61B |
| Straumann Holding AG | 2.61B |
Roche Holding AG News
- 3 hours ago - Roche's Divarasib Meets Primary Endpoint In Phase 3 Krascendo 1 Study For Treating Lung Cancer - Nasdaq
- 5 hours ago - Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial - WSJ
- 19 hours ago - Roche to set up digital technology hub in Hyderabad - The Times of India
- 1 day ago - Old cancer drug may help restore fertility for certain women - Reuters
- 2 days ago - Genentech announces priority review for Enspryng - TheFly
- 2 days ago - Roche Secures FDA Priority Review Of Enspryng In Thyroid Eye Disease; Decision Due October 2026 - Nasdaq
- 2 days ago - FDA Grants Priority Review To Genentech's Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED) - Business Wire
- 3 days ago - Roche announces launch of AXELIOS 1, a next-gen sequencing platform - TheFly